Evidence Table A2. CONTINUOUS outcomes for class CLEANSER (TOPICAL)

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	A.01.01			**Acidic syndet bar**		**Soap**		
197 ↑ N=114 Parallel Mild		**Inflammatory (count)** Baseline counts: 13 (Target) / 15		Percent Change*: -22	*.0001*	Percent Change*: 05	*.0001*	**NS***
		Non-inflammatory (count) Baseline counts: 7 (Target) / 7 (Comparator)	Mid (12)	Percent Change*: -12		Percent Change*: 31		**NS***
	A.01.05			**Silicic acid**		**Vehicle**		
204 ↑ N=30 Parallel Mod		**Comedones (count)** Count location: Left cheek.	Short (6)	Raw count: 15 (66.)	*.01*	Raw count: 46	*NS*	**NS**
		Cysts (count) Count location: Left cheek. Baseline counts: 1 (Target) / 0 (Comparator)	Short (6)	Percent Change*: -100		Percent Change*: -25	*NS*	
		Papules (count) Count location: Left cheek. Baseline counts: 11 (Target) / 11 (Comparator)	Short (6)	Percent Change*: -91	*.001*	Percent Change*: 00	*NS*	**NS**
		Pustules (count) Count location: Left cheek. Baseline counts: 7 (Target) / 6 (Comparator)	Short (6)	Percent Change*: -100	*.0001*	Percent Change*: -06	*.01*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.